A technique for separating viable islets of Langerhans from a fragment of human pancreatic tail

Introduction. Modern techniques of tissue engineering in the treatment of some degenerative diseases suggest the prospective viability of the biomedical technologies based on the creation of the equivalent of the damaged tissue (organ), including the tissue-engineered construct (TEC) of the endocrine pancreas (EP). Obtaining viable islets of Langerhans (IL) from the pancreas is a decisive step towards the creation of a TEC EP. The classic method of IL separation is based on enzymatic digestion of pancreatic tissue and further islet purification in ficoll density gradient during centrifugation, which adversely affects the morphofunctional state of IL.

The aim of the study was the development of a method for separating viable pancreatic islets from a fragment of human pancreatic tail with different cold ischemia times.

Materials and methods. A procedure of IL separation is proposed to be conducted without the use of EP tissue collagenase perfusion in the Ricordi chamber at the stage of IL separation and without ficoll solution with a varying density gradient at the stage of IL purification. Identification of IL obtained was performed by dithizone staining. The IL viability was evaluated using the LIVE/DEAD ® Cell Viability Kit. Histological analysis of the initial material included routine staining methods as well as immunohistochemical staining of the main types of islet cells.

Results. The morphological study of the EP fragments at different times of cold ischemia did not reveal significant differences in the histological presentation of the organ parenchyma; the islet structure appeared intact. Vital staining confirmed the separated IL viability in vitro for at least 1–3 days.

Conclusion. The proposed method of pancreatic tissue treatment allowed to reduce the number of stages, thereby minimizing the adverse effects of centrifugation and ficoll on the integrity of IL. It is possible to obtain the necessary amount of viable IL from a small EP fragment with the cold ischemia time of up to 19 hours, which can be used to create a TEC of a pancreas.

1. Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. PNAS. 2015; 112 (47): 14452–14459. doi: 10.1073/pnas.1508520112.

2. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012 Jul; 35 (7): 1436–1445. doi: 10.2337/dc12-0063.

3. Matsumoto S. Islet cell transplantation for type 1 diabetes. J Diabetes. 2010 Mar; 2 (1): 16–22. doi: 10.1111/j.1753-0407.2009.00048.x.

4. Van Bell TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011 Jan; 91 (1): 79–118. doi: 10.1152/physrev.00003.2010.

5. Gan MJ, Albanese­O’Neill A, Haller MJ. Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research. Curr Probl Pediatr Adolesc Health Care. 2012 Nov-Dec; 42 (10): 269–291. doi: 10.1016/j.cppeds.2012.07.002.

6. Ehlers MR. Strategies for clinical trials in type 1 diabetes. J Autoimmun. 2016 Jul; 71: 88–96. doi: 10.1016/j.jaut2016.03.008.

7. Ziegler M, Ziegler B. Immunological disorders of type 1 diabetes mellitus. Exp Clin Endocrinol. 1989 Sep; 94 (1–2): 97–114.

8. Wahren J., Larsson C. C-peptide: new findings and therapeutic possibilities. Diabetes Res Clin Pract. 2015 Mar; 107 (3): 309–319. doi: 10.1016/j.diabres.2015.01.016.

9. Kiriyama Y, Nochi H. Role and cytotoxicity of amylin and protection of pancreatic islet β-cells from amylin cytotoxicity. Cells. 2018 Aug 6; 7 (8). pii: E95. doi: 10.3390/cells7080095.

10. Bottino R, Knoll MF, Knoll CA, Bertera S, Trucco MM. The future of islet transplantation is now. Front Med (Lausanne). 2018 Jul 13; 5: 202. doi: 10.3389/fmed.2018.00202.

11. Jamiolkowski RM, Guo LY, Li YR, Shaffer SM, Naji A, Yale J. Islet transplantation in type 1 diabetes mellitus. Yale J Biol Med. 2012 Mar; 85 (1): 37–43.

12. Shapiro AM, Pokrywczynska M, Ricordi C.Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017 May; 13 (5): 268–277. doi: 10.1038/nrendo.2016.178.

13. Maffi P, Secchi A.Clinical results of islet transplantation. Pharmacol Res. 2015 Aug; 98: 86–91. doi: 10.1016/jphrs.2015.04.010.

14. Merani S, Shapiro AM. Current status of pancreatic islet transplantation. Clin Sci(Lond). 2006 Jun; 110 (6): 611–625.

15. Amer LD, Mahoney MJ, Bryant SJ. Tissue engineering approaches to cell-based type 1 diabetes therapy. Tissue engineering. 2014; Part B, 20 (5): 455–467. doi: 10.1089/ten.TEB.2013.0462.

16. Pileggi A, Fenjves ES, Klein D, Ricordi C, Pastori RL. Protecting pancreatic beta-cells. IUBMB Life. 2004 Jul; 56 (7): 387–394.

17. Timofeev AV. A cell-population structure of the pancreas and the use of cellular technology in the treatment of diabetes. Stem cell biology and cellular technologies. 2009; 2: 253–310.

18. Kelly C, Mc Clenaghan NH, Flatt PR. Role of islet structure and cellular interactions in the control of insulin secretion. Islets. 2011 Mar-Apr; 3 (2): 41–47.

19. Ricordi C, Hering BJ, Shapiro AM. Beta-cell transplantation for diabetes therapy. Lancet. 2008 Jul 5; 372 (9632): 27–28. doi: 10.1016/S0140-6736(08)60984-8.

20. Matsumoto S, Noguchi H, Yonekawa Y, Okitsu T, Iwanaga Y, Liu X et al. Pancreatic islet transplantation for treating diabetes. Expert Opin Biol Ther. 2006 Jan; 6 (1): 23–37.

21. Paget M, Murray H, Bailey CJ, Downing R. Human islet isolation: semi-automated and manual methods. Diabetes & Vascular Disease Research. 2007; 4: 7–12. doi: 10.3132/dvdr.2007.010.

22. Min T, Yi L, Chao Z, Haitao Z, Wei W, Liang Y et al. Superiority of visipaque (iodixanol) – controlled density gradient over Ficoll-400 in adult porcine islet purification. Transplant Proc. 2010 Jun; 42 (5): 1825–1829. doi: 10.1016/j.transproceed.2010.01.068.